Clinical and Pathologic Response to Neoadjuvant Chemotherapy for Breast Cancer

项目摘要/摘要：乳腺癌中的VICC孢子(P50CA098131) 本申请是为了回应被确认为非CA-CA的特殊利益通知(NOSI)而提交的 23-038. 范德比尔特-英格拉姆癌症中心(VICC)乳腺癌孢子的总体目标是进行 协作性、多学科和基于机制的翻译研究将具有最高的可能 对患有或有患乳腺癌风险的女性和男性的影响。本项目为#年的行政副刊 NCI全球肿瘤学指导研究将评估乳腺癌新辅助化疗的反应 在肯尼亚Kijabe通过正式的指导研究关系接受乳腺癌治疗的患者 范德比尔特大学医学中心的研究人员和一名教职员工(一名医务人员 肿瘤专家/放射肿瘤专家)在AIC Kijabe医院。克里斯汀·姆瓦基奥博士(医学/放射肿瘤学)是 职业生涯早期的中低收入国家研究员(ESLI)，积极参与乳腺癌的护理 肯尼亚的病人。她提出了一项由两部分组成的研究。首先，她将评估新佐剂的临床反应。 化疗疗效与患者人口学、肿瘤的关系 初诊乳腺癌患者的特征、健康的社会决定因素和治疗方案 Kijabe医院。其次，她将比较乳腺癌的分子亚型和对新佐剂的反应 化疗，与肯尼亚基贾贝的残留癌症负担评分相关。来自本分包合同的资金将 支持ESLI的工资，两名研究助理，笔记本电脑的研究助理来完成这一点 项目，用于对乳房活检标本和手术乳房进行免疫组织化学分析 标本，并利用公共交通工具让研究中的患者返回肯尼亚基贾贝进行随访。Dr。 本·帕克(内科肿瘤学)和朗迪·考夫曼博士(乳腺外科肿瘤学)组成了这项研究 范德比尔特的指导团队。作为主要导师，考夫曼博士将负责职业发展和 为耶斯利大学提供研究项目指导。在这个角色中，她将每周通过Zoom与她会面，将旅行一次 在肯尼亚的Kijabe接受了一年的培训，并将在这一年中在范德比尔特主办一次Esli培训。

PROJECT SUMMARY/ABSTRACT: VICC SPORE IN BREAST CANCER (P50CA098131) This application is being submitted in response to the Notice of Special Interest (NOSI) identified as NOT-CA- 23-038. The overall goal of the Vanderbilt-Ingram Cancer Center (VICC) SPORE in Breast Cancer is to conduct collaborative, multidisciplinary and mechanism-based translational research that will have the highest possible impact for women and men with or at risk for breast cancer. This project for the Administrative Supplement for NCI Global Oncology Mentored Research will assess response to neoadjuvant chemotherapy for breast cancer in patients undergoing breast cancer treatment in Kijabe, Kenya through a formal mentored research relationship between researchers at Vanderbilt University Medical Center and a faculty member (a medical oncologist/radiation oncologist) at AIC Kijabe Hospital. Dr. Christine Mwakio (medical/radiation oncology) is an early-career low-middle income country researcher (ESLI) who is actively involved in the care of breast cancer patients in Kenya. She proposes a two-part study. First, she will evaluate the clinical response to neoadjuvant chemotherapy and the relationship between response to therapy and patient demographics, tumor characteristics, social determinants of health and treatment regimen in patients diagnosed with breast cancer at Kijabe Hospital. Second, she will compare the molecular subtypes of breast cancer with response to neoadjuvant chemotherapy, correlating with residual cancer burden score in Kijabe, Kenya. Funds from this subcontract will support the salary of the ESLI, two research assistants, laptops for the research assistants to complete this project, funds to perform immunohistochemistry analysis on both breast biopsy specimens and surgical breast specimens, and use of public transportation for patients in the study to return to Kijabe, Kenya for follow-up. Dr. Ben Park (medical oncology) and Dr. Rondi Kauffmann (breast surgical oncology) comprise the research mentoring team at Vanderbilt. As primary mentor, Dr. Kauffmann will be responsible for career development and research project mentoring for the ESLI. In that role, she will meet with her weekly via zoom, will travel once to Kijabe, Kenya for training during the year, and will host the ESLI for training at Vanderbilt once during the year.